Riverhead Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Riverhead Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$86K	Hold	1,517	–	–	﹤0.01%	1363
2019 Q2	$84K	Hold	1,517	–	–	﹤0.01%	1380
2019 Q1	$77K	Hold	1,517	–	–	﹤0.01%	1379
2018 Q4	$61K	Buy	1,517 +200	+15%	+$10.3K	﹤0.01%	1392
2018 Q3	$91K	Buy	1,317 +100	+8%	+$7.58K	﹤0.01%	1414
2018 Q2	$92K	Hold	1,217	–	–	﹤0.01%	1361
2018 Q1	$64K	Buy	1,217 +200	+20%	+$11.6K	﹤0.01%	1431
2017 Q4	$54K	Buy	1,017 +200	+24%	+$11.1K	﹤0.01%	1465
2017 Q3	$49K	Buy	817 +251	+44%	+$15.2K	﹤0.01%	1449
2017 Q2	$45K	Buy	566 +266	+89%	+$21.8K	﹤0.01%	1435
2017 Q1	$25K	Buy	+300	New	+$22.3K	﹤0.01%	1439

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Riverhead Capital Management's EGRX Position: Q3 2019 in Review

Riverhead Capital Management held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q3 2019 at 1,517 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #1363.

Riverhead Capital Management first reported a position in EGRX in Q1 2017 and has held it in 11 quarters since. The position peaked at $92K in Q2 2018. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

Riverhead Capital Management held 1,517 shares of Eagle Pharmaceuticals, Inc. worth $86K as of Q3 2019.
Riverhead Capital Management left its Eagle Pharmaceuticals, Inc. share count unchanged in Q3 2019.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1363 holding.
Riverhead Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and has held it in 11 quarters since.
Riverhead Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $92K in Q2 2018.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.